Please login to the form below
Vertex Pharma
This page shows the latest Vertex Pharma news and features for those working in and with pharma, biotech and healthcare.
Vertex continues upward trajectory with French Orkambi deal
The American pharma giant reached an agreement with the English regulatory bodies in October, for access to Orkambi and Vertex’s other CF treatments Symkevi (tezacaftor-ivacaftor) and Kalydeco (ivacaftor). ... Vertex has also submitted the triple
Latest news
-
Vertex reveals promising data from first CRISPR-treated patients
beta thalassemia,” said Jeffrey Leiden (pictured left), president and chief executive officer of Vertex. ... Vertex paid CRISPR Therapeutics $105m upfront in 2015, with up to $420m in milestone payments, to tap into its gene-editing expertise.
-
Vertex, NHS England and NICE finally reach agreement for Orkambi
to treat the underlying cause of their disease,” said Ludovic Fenaux (pictured right), senior vice president, Vertex International. ... We are pleased an agreement has been reached between NHS England and Vertex that brings these medicines to patients.
-
Vertex scores FDA approval for CF triple therapy Trikafta
The approval comes only a few months after Vertex filed the triple therapy with the FDA. ... Vertex has also submitted the triple therapy to the European Medicines Agency, with a decision expected in 2020.
-
Vertex scores CF deal with Scotland, but access debate continues
This is the first agreement within the UK for access to Vertex's CF medicines, and comes following a long history of pricing disagreements, most notably between the pharma company, NHS ... The NHS in England offered £500m over five years and £1bn over
-
Vertex eyes type 1 diabetes cure with biotech acquisition
Will acquire Semma Therapeutics for $950m. American pharma company Vertex will acquire Semma Therapeutics, a biotech focused on finding a cure for type 1 diabetes. . ... According to Vertex, the biotech is pioneering the use of stem cells as a potential
More from news
Approximately 6 fully matching, plus 47 partially matching documents found.
Latest Intelligence
-
The Cystic Fibrosis Buyers’ Club
This includes overriding pharma patents – something the group is advocating in relation to three drugs – Vertex’s cystic fibrosis treatment Orkambi, Pfizer’s breast cancer treatment Ibrance and Roche’s breast ... Meticulous preparations. The
-
Vertex: a vision of treating all CF patients worldwide draws closer
Its high prices are controversial, but Vertex also embodies the best of biopharma drug development. ... The failure of Proteostasis has led analysts to upgrade forecasts for Vertex’s own franchise.
-
The Orkambi blame game
The deadlock between pharma company Vertex and NHS England over cystic fibrosis drug Orkambi was played out in a parliamentary hearing in London on 7 March, when the company’s CEO ... NHS England accusing Vertex of being an“extreme outlier” and
-
2019: CRISPR and therapeutic gene editing comes of age
The green light came after a delay of around a year caused by manufacturing issues, which allowed another candidate from CRISPR Therapeutics and Vertex Pharma - CTX001 for the rare blood disease
-
The challenges of making genomics a reality for patients today, not tomorrow
and higher risk science. The report singles out Vertex among a handful of successful biotech companies with highly innovative products. ... Dr Gillian Burgess is site head of UK Research and Vice President at Vertex.
More from intelligence
Approximately 1 fully matching, plus 6 partially matching documents found.
Latest appointments
-
Vertex poaches new finance chief from Ironwood Pharmaceuticals
Boston-based biotech company appoints Tom Graney. Vertex lured Tom Graney away from Ironwood Pharmaceuticals, appointing him as its new senior vice president and chief financial officer. ... Tom has the ideal blend of financial acumen, leadership skills,
-
BMS appoints three independent directors
Meanwhile, Matthew Emmens and Theodore Samuels also join the pharma firm's board of directors. ... Since beginning his pharmaceutical career 40 years ago, Emmens has served as president, chief executive officer and chairman of Vertex Pharma, chief
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
Frontera Group
Dreamskin Health . Eusa Pharma. Galderma . Gedeon Richter. Genzyme. Grunenthal . Leukaemia UK. ... Novartis Pharmaceuticals. Novex Pharma. Pfizer. Shire Pharmaceuticals. UCB . Vertex Pharmaceuticals.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Regeneron says antibody for COVID-19 could be ready this year
- EMA clears BMS’ oral multiple sclerosis drug Zeposia
- Amgen adds Otezla to the COVID-19 candidate list
- Guiding star of science leads AstraZeneca to breakthrough in child tumour therapy
- New data backs remdesivir for COVID-19, but rings hydroxychloroquine alarm bell
- Alnylam and Vir plan gene-silencing attack on COVID-19 virus
- ASCO: Momentum gathers behind next wave of CAR-T therapies
- Lilly starts world first trial of an antibody drug for COVID-19
- Pfizer’s Ibrance misses the mark in early breast cancer
- Rise of the patient influencer
- Working together against COVID-19
- Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
PMHub
Wordbird
Wordbird is a healthcare communications agency with creative, compelling copy at its heart....
Latest intelligence
- Working together against COVID-19
- Analysing social media conversations to see what HCPs are saying online about the global pandemic...
- Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
- Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
- Are biobetters a market access opportunity?
- Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....
Quick links
Infographics
